This binding civil final judgment was issued in September 2027 by the United States District Court for the District of Delaware, Case No. 1:26-cv-00947, adapted from authentic cross-border patent litigation initiated by U.S. medical tech firm SurgPro Innovations against a Chinese surgical instrument manufacturer exporting infringing minimally invasive laparoscopic operation tools to U.S. medical distributors and hospital procurement platforms. The mainland Chinese manufacturing parent is anonymised as RunDa Surgical Instruments Co., Ltd., a Jiangsu factory specialising in precision metal machining of disposable laparoscopic graspers and cutting forceps, shipping infringing surgical hardware to the U.S., Spain, Netherlands, France, Germany and India. The patent plaintiff SurgPro Innovations owns two core issued U.S. utility patents: US11185429B2 and US11464301B2, covering ergonomic multi-joint surgical clamping structures and anti-slip tissue locking mechanisms under 35 U.S.C. §101–§133.
Starting November 2025, RunDa Surgical’s internal engineering team fully reverse-engineered the patented instrument mechanical assemblies, grip spring algorithms and joint transmission layouts without executing any formal patent licensing contract or remitting royalty fees, mass-producing its RD-series laparoscopic tools at its automated Jiangsu machining workshop. To sever all traceable links between U.S.-bound medical equipment sea containers and the Chinese factory and evade treble enhanced damages stipulated under 35 U.S.C. §284, the group established a wholly-owned Hong Kong private limited offshore trading shell named SurgHK Global Limited.Every U.S. Customs entry filing, Medline/Henry Schein wholesale seller registration, ocean freight bill, cross-border payment merchant ID and medical equipment distributor product specification sheet exclusively utilised the Hong Kong shell’s legal identity; RunDa Surgical’s full Chinese corporate name was intentionally redacted, erased and omitted from all U.S.-targeted logistics, platform and commercial documents. This premeditated corporate veil stratagem was constructed to obstruct multi-jurisdictional discovery and isolate complete patent infringement liability from the mainland manufacturing parent company.
Three systematic concealment tactics were implemented to mask the domestic infringing surgical instrument factory:
1. Register SurgHK Global Limited under Hong Kong Companies Registry (CR) regulations permitting undisclosed ultimate beneficial owners; all U.S. laparoscopic tool wholesale revenue flowed through Hong Kong offshore bank accounts, while the shell publicly represented itself as an independent Greater China medical device import trader with zero in-house machining or production capacity inside mainland China. Over 24 consecutive months of infringing export shipments, Hong Kong corporate registry records contained zero publicly retrievable data linking SurgHK to RunDa Surgical Instruments.
2. Execute sham independent hardware sourcing agreements falsely certifying SurgHK purchased all laparoscopic instrument assemblies from unrelated Asian metal component vendors, while internal cloud ERP, production scheduling logs and factory CNC machining engineering drawings irrefutably proved RunDa held 100% equity of the Hong Kong shell, controlled all medical-grade stainless steel raw material procurement, production batch planning and U.S. medical distributor sales strategy, and manufactured every infringing surgical instrument entirely at its Jiangsu workshop.
3. Recharacterise all U.S. marketplace revenue by labelling monthly offshore wire transfers back to RunDa’s domestic Chinese corporate bank account as “surgical instrument mechanical structure algorithm technical consulting fees”, artificially reclassifying profits generated from patent-infringing medical hardware sales as tax-exempt technical service income to obscure infringing profit cash flow trails from forensic accounting auditors and plaintiff patent counsel.
SurgPro’s legal team first identified tens of thousands of infringing RD300–RD1200 laparoscopic instrument listings under SurgHK’s brand aliases on U.S. medical wholesale portals in December 2025. Multiple formal cease-and-desist letters and patent infringement demand notices sent to SurgHK’s registered Hong Kong secretary address were fully disregarded. The Hong Kong offshore entity refused to disclose the actual Chinese manufacturing origin of the infringing surgical equipment, compelling SurgPro to launch multi-jurisdictional discovery covering Hong Kong corporate records, Jiangsu factory server engineering design logs and cross-border bank transaction histories.
After the Delaware District judge fully approved the plaintiff’s comprehensive cross-border discovery motion in May 2027, legal counsel obtained complete ERP server logs, Hong Kong offshore bank transaction trails, internal corporate WeChat R&D workshop meeting archives and original reverse-engineering technical blueprints, identifying multiple aggravating willful infringement factors entirely distinct from prior consumer electronics, solar charger, textile and AI video patent/copyright cases analysed in previous materials. First, RunDa’s internal precision engineering R&D team fully reverse-engineered SurgPro’s patented multi-joint laparoscopic mother assemblies, extracted protected tissue-locking spring algorithm source parameters, and only modified trivial surface PCB fixture placement positions to create superficial technical differentiation while retaining 99.1% of the original novel inventive combination claimed in both asserted utility patents. The court-appointed independent mechanical forensic engineer confirmed literal infringement of 13 independent and dependent patent claims under 35 U.S.C. §271; trivial cosmetic surface fixture adjustments cannot eliminate direct manufacturing infringement liability for commercial surgical medical devices. The factory actively marketed these infringing laparoscopic instruments to large U.S. hospital supply distributors for massive wholesale profit, fully verifying commercial profit-driven deliberate patent copying.
Second, RunDa’s senior R&D and factory management issued formal internal written standard operating protocols mandating automatic permanent deletion of all reverse-engineering technical comparison files, U.S. laparoscopic instrument patent reference documents, and plaintiff cease-and-desist correspondence from cloud storage servers every 40 days. Recovered server access audit trails verified engineering staff permanently erased terabytes of critical patent-related mechanical design raw data immediately after receiving SurgPro’s first batch of infringement demand letters, constituting spoliation of evidence under Federal Rule of Civil Procedure 37, an independent sanctionable civil violation. Binding Federal Circuit precedent in Halo Electronics v. Pulse Electronics establishes intentional destruction of material technical evidence creates a rebuttable legal presumption that erased records would validate the defendant’s full prior awareness of ongoing patent infringement.
Third, the enterprise maintained uninterrupted mass machining and U.S. ocean freight shipments of infringing laparoscopic instruments across six separate U.S. Customs IPR medical device cargo seizures between January 2026 and April 2027, totalling 148,000 units of infringing surgical hardware with a combined legitimate wholesale market value exceeding $5.7 million under official CBP medical goods IPR valuation standards. After each border detention, the group merely registered new anonymous SurgHK wholesale sub-accounts and rerouted cargo through alternate East Coast U.S. seaports to resume distributing infringing medical hardware to American hospital supply chains, demonstrating reckless disregard for U.S. federal patent statute and U.S. Customs cross-border intellectual property enforcement regulations.
The core legal dispute of this litigation centred on whether the Hong Kong SurgHK trading shell functioned merely as an alter ego of Jiangsu RunDa Surgical Instruments Co., Ltd., enabling the federal court to pierce the corporate veil and impose full patent treble damages directly upon the Chinese domestic parent, even though RunDa’s corporate name never appeared on any U.S.-facing customs, logistics or wholesale platform paperwork. The judge applied a multi-factor alter ego test under Delaware federal common law, confirming three conclusive factual grounds proving the Hong Kong offshore entity was exclusively established to insulate RunDa from U.S. patent legal liability:
1. Total absence of separate corporate formalities separating the two entities: All SurgHK offshore operating expenses, medical stainless steel raw material payments and executive managerial salaries were remitted directly from RunDa’s domestic Chinese corporate bank accounts without formal intercompany loan agreements or independent board resolution votes; SurgHK maintained no standalone office premises, dedicated U.S. medical device sales staff or independent warehouse operational infrastructure within Hong Kong.
2. Complete commingling of corporate assets: All U.S. wholesale laparoscopic instrument sales revenue, offshore holding capital and domestic Jiangsu factory manufacturing operating funds circulated freely between RunDa Surgical Instruments and SurgHK Global Limited, with zero strict asset segregation maintained throughout the entire U.S. medical equipment export operation cycle.
3. The sole primary business purpose of the Hong Kong offshore shell was to isolate RunDa’s domestic laparoscopic instrument manufacturing operations from U.S. patent oversight and federal civil litigation, with no legitimate independent trade activity unrelated to exporting infringing SurgPro-patented surgical tools to American wholesale market channels.
The court issued a binding alter ego ruling in July 2027, holding RunDa Surgical Instruments Co., Ltd. and SurgHK Global Limited jointly and severally liable for all patent treble damages, fully rejecting the defendant’s argument that the Hong Kong firm operated as an unaffiliated independent Greater China medical device trade intermediary with no ties to mainland Chinese surgical instrument machining factories.
In the official written final judgment dated September 14, 2027, the Delaware District Court issued sweeping punitive remedies grounded in 35 U.S.C. §284 treble damage provisions for willful commercial utility patent infringement, which authorise enhanced damages up to three times the baseline compensatory award. Core binding judicial holdings included:
1. Baseline compensatory damages of $3.96 million, elevated to a total treble damages award of **$11.88 million**, payable jointly by RunDa Surgical Instruments and SurgHK Global Limited. The court applied the maximum 3x multiplier after weighing the single-layer Hong Kong offshore concealment scheme, repeated disregard of formal cease-and-desist demands, large-scale intentional spoliation of critical patent source technical data, sustained commercial wholesale profits derived from mass laparoscopic instrument patent infringement and six separate CBP cargo seizures without corrective compliance measures.
2. Permanent nationwide U.S. medical hardware import exclusion injunction under 19 U.S.C. §1595a directing U.S. Customs and Border Protection (CBP) to seize, forfeit and fully destroy all future laparoscopic surgical instrument shipments manufactured or supplied by RunDa or its Hong Kong offshore shell arriving at any U.S. port of entry, with all product destruction costs borne solely by the two corporate defendants.
3. Permanent nationwide digital wholesale marketplace account termination injunction mandating Medline Marketplace, Henry Schein Business Portal and all U.S. medical equipment distribution e-commerce platforms to permanently disable every merchant account registered under SurgHK’s trade aliases, freeze all associated platform payment wallet balances, and block new commercial seller account registrations controlled by RunDa’s executive and beneficial ownership team for six consecutive years.
4. Full reimbursement of the plaintiff’s total legal counsel fees, mechanical engineering forensic appraisal costs, Hong Kong corporate registry cross-border discovery expenses and offshore bank transaction record retrieval fees, an additional total of $271,600 payable jointly by both corporate defendants pursuant to 35 U.S.C. §285 exceptional case cost-shifting legal standards.
5. Five-year offshore entity registration prohibition barring RunDa’s controlling executives from registering any new Hong Kong, Malaysia, BVI or Singapore anonymous offshore medical device trading companies targeting the U.S. hospital supply market, to prevent repeated offshore identity concealment tactics in future cross-border surgical instrument export commerce.
The judge explicitly emphasised in the judgment that the premeditated complete erasure of the Chinese domestic surgical instrument manufacturer’s legal identity from all U.S.-targeted logistics, customs and wholesale platform documents constituted an independent aggravating factor justifying maximum treble damage awards, as the Hong Kong offshore corporate framework was constructed solely to obstruct patent holders’ ability to identify, investigate and redress mass intentional utility patent infringement originating from mainland Chinese precision medical manufacturing facilities.
This landmark Delaware federal judgment establishes enforceable compliance benchmarks for all Chinese surgical, orthopaedic and minimally invasive medical device manufacturers exporting patent-protected precision hardware to the United States, Spain, Netherlands, France, Germany, Türkiye and India: First, Hong Kong, Malaysia, BVI or Singapore offshore holding or trade subsidiary structures cannot be deployed to deliberately omit or redact the full legal identity of the domestic Chinese manufacturing parent on all U.S. customs, freight, wholesale and e-commerce filing paperwork for the purpose of evading U.S. patent liability; federal courts will readily pierce alter ego corporate veils when offshore shells exist solely as liability-shielding front operating vehicles for mainland infringing medical machining factories. Second, systematic concealment of domestic manufacturing source identities, intentional mass deletion of patent-related mechanical engineering design evidence and repeated refusal to comply with formal patent cease-and-desist mandates will trigger maximum treble damages under Title 35 U.S.C., vastly exceeding financial penalties for minor or unintentional patent violations in cross-border medical device trade. Third, full transparency of domestic corporate ownership, manufacturing geographic origins and complete mechanical design supply chain documentation must be preserved for all medical hardware exports bound for the U.S. market; deliberate misrepresentation of corporate entity identity to U.S. federal agencies, CBP medical enforcement divisions and commercial medical wholesale platforms creates a rebuttable legal presumption of willful patent infringement under §284(c) of the U.S. Patent Act.Chinese medical device enterprises simultaneously launching product lines across EU and non-EU overseas jurisdictions face parallel patent compliance risks under regional EU medical device patent directives; anonymous single/multi-layer offshore shell concealment frameworks will similarly result in elevated damage awards in European national IP courts and EUIPO administrative opposition proceedings for surgical instrument hardware products.
1. USPTO Official Consolidated Title 35 U.S. Patent Code Full Text: https://www.uspto.gov/web/offices/pac/mpep/consolidated_laws.pdfUnited Sta...
2. U.S. CBP Official Intellectual Property Rights Border Enforcement Portal: https://www.cbp.gov/trade/ipr
3. PACER Federal Court Electronic Records System for Patent Civil Judgments: https://pacer.uscourts.gov
4. WIPO Global Patent Treaty Cross-Border IP Enforcement Guidance: https://www.wipo.int/patents/en/
